Combined Side Effects During Days 1–5 in the Postexposure Prophylaxis and Early Treatment Cohorts
| . | Hydroxychloroquine, No. (%) . | Placebo, No. (%) . | P Value . |
|---|---|---|---|
| No. randomized | 658 | 654 | |
| Started study medication | 576 (87.5) | 563 (86.1) | .46 |
| Any side effect (days 1–5)a | 231 (40.1) | 101 (17.9) | <.001 |
| Side effectsa | |||
| Nausea or upset stomach | 146 (25.3) | 53 (9.4) | <.001 |
| Diarrhea, abdominal pain, vomiting | 131 (22.7) | 35 (6.2) | <.001 |
| Irritability, dizziness, vertigo | 39 (6.8) | 26 (4.6) | .13 |
| Tinnitus | 16 (2.8) | 8 (1.4) | .15 |
| Headache | 15 (2.6) | 8 (1.4) | .21 |
| Visual changes | 7 (1.2) | 5 (0.9) | .77 |
| Skin reaction | 10 (1.7) | 4 (0.7) | .18 |
| Taste change or dry mouth | 3 (0.5) | 3 (0.5) | >.99 |
| Allergic reaction | 6 (1.0) | 1 (0.2) | .12 |
| Hot flashes, night sweats, or palpitations | 2 (0.3) | 1 (0.2) | >.99 |
| Fatigue | 1 (0.2) | 1 (0.2) | >.99 |
| Panic | 0 (0.0) | 1 (0.2) | .49 |
| Other | 1 (0.2) | 2 (0.4) | .62 |
| . | Hydroxychloroquine, No. (%) . | Placebo, No. (%) . | P Value . |
|---|---|---|---|
| No. randomized | 658 | 654 | |
| Started study medication | 576 (87.5) | 563 (86.1) | .46 |
| Any side effect (days 1–5)a | 231 (40.1) | 101 (17.9) | <.001 |
| Side effectsa | |||
| Nausea or upset stomach | 146 (25.3) | 53 (9.4) | <.001 |
| Diarrhea, abdominal pain, vomiting | 131 (22.7) | 35 (6.2) | <.001 |
| Irritability, dizziness, vertigo | 39 (6.8) | 26 (4.6) | .13 |
| Tinnitus | 16 (2.8) | 8 (1.4) | .15 |
| Headache | 15 (2.6) | 8 (1.4) | .21 |
| Visual changes | 7 (1.2) | 5 (0.9) | .77 |
| Skin reaction | 10 (1.7) | 4 (0.7) | .18 |
| Taste change or dry mouth | 3 (0.5) | 3 (0.5) | >.99 |
| Allergic reaction | 6 (1.0) | 1 (0.2) | .12 |
| Hot flashes, night sweats, or palpitations | 2 (0.3) | 1 (0.2) | >.99 |
| Fatigue | 1 (0.2) | 1 (0.2) | >.99 |
| Panic | 0 (0.0) | 1 (0.2) | .49 |
| Other | 1 (0.2) | 2 (0.4) | .62 |
P values were calculated using the chi-square test.
aOf those who started study medication.
Combined Side Effects During Days 1–5 in the Postexposure Prophylaxis and Early Treatment Cohorts
| . | Hydroxychloroquine, No. (%) . | Placebo, No. (%) . | P Value . |
|---|---|---|---|
| No. randomized | 658 | 654 | |
| Started study medication | 576 (87.5) | 563 (86.1) | .46 |
| Any side effect (days 1–5)a | 231 (40.1) | 101 (17.9) | <.001 |
| Side effectsa | |||
| Nausea or upset stomach | 146 (25.3) | 53 (9.4) | <.001 |
| Diarrhea, abdominal pain, vomiting | 131 (22.7) | 35 (6.2) | <.001 |
| Irritability, dizziness, vertigo | 39 (6.8) | 26 (4.6) | .13 |
| Tinnitus | 16 (2.8) | 8 (1.4) | .15 |
| Headache | 15 (2.6) | 8 (1.4) | .21 |
| Visual changes | 7 (1.2) | 5 (0.9) | .77 |
| Skin reaction | 10 (1.7) | 4 (0.7) | .18 |
| Taste change or dry mouth | 3 (0.5) | 3 (0.5) | >.99 |
| Allergic reaction | 6 (1.0) | 1 (0.2) | .12 |
| Hot flashes, night sweats, or palpitations | 2 (0.3) | 1 (0.2) | >.99 |
| Fatigue | 1 (0.2) | 1 (0.2) | >.99 |
| Panic | 0 (0.0) | 1 (0.2) | .49 |
| Other | 1 (0.2) | 2 (0.4) | .62 |
| . | Hydroxychloroquine, No. (%) . | Placebo, No. (%) . | P Value . |
|---|---|---|---|
| No. randomized | 658 | 654 | |
| Started study medication | 576 (87.5) | 563 (86.1) | .46 |
| Any side effect (days 1–5)a | 231 (40.1) | 101 (17.9) | <.001 |
| Side effectsa | |||
| Nausea or upset stomach | 146 (25.3) | 53 (9.4) | <.001 |
| Diarrhea, abdominal pain, vomiting | 131 (22.7) | 35 (6.2) | <.001 |
| Irritability, dizziness, vertigo | 39 (6.8) | 26 (4.6) | .13 |
| Tinnitus | 16 (2.8) | 8 (1.4) | .15 |
| Headache | 15 (2.6) | 8 (1.4) | .21 |
| Visual changes | 7 (1.2) | 5 (0.9) | .77 |
| Skin reaction | 10 (1.7) | 4 (0.7) | .18 |
| Taste change or dry mouth | 3 (0.5) | 3 (0.5) | >.99 |
| Allergic reaction | 6 (1.0) | 1 (0.2) | .12 |
| Hot flashes, night sweats, or palpitations | 2 (0.3) | 1 (0.2) | >.99 |
| Fatigue | 1 (0.2) | 1 (0.2) | >.99 |
| Panic | 0 (0.0) | 1 (0.2) | .49 |
| Other | 1 (0.2) | 2 (0.4) | .62 |
P values were calculated using the chi-square test.
aOf those who started study medication.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
